Roughly one in six Australian adults takes an antidepressant. Two in three live with overweight or obesity. The overlap is large, larger than coincidence, and larger than most clinical conversations make room for.
When the two collide, the conversation tends to go quiet. A person whose depression has lifted on medication, but whose body has gained five, ten, fifteen kilos, is often told some version of that’s just how it goes, or worse, that they need to try harder at the lifestyle side. Both responses miss something important. So at Anova, we want to lay out what the evidence shows about this bind, and what are some questions that medicine has not finished answering.
What antidepressants do to weight, in numbers
The body-weight effects of antidepressants are not uniform. They vary substantially by drug, dose, and duration, and the older meta-analyses and newer cohorts disagree at the edges. But the broad pattern is reasonably well-established.
A 2025 Lancet network meta-analysis of antidepressants and cardiometabolic parameters reported clinically significant differences between agents, including roughly a 4 kg spread in weight change between the lightest and heaviest options over a short course of treatment; the review found that antidepressants differ meaningfully in their short-term weight effect, with some agents associated with weight gain in a substantial proportion of patients. (This network meta-analysis covers roughly 8 weeks of treatment, so it speaks to short-term rather than long-term weight change.) A 2018 BMJ cohort study following nearly 300,000 people over ten years found approximately a 29% higher rate of transition to overweight or obesity on antidepressants as a class compared to non-use (adjusted rate ratio 1.29), sustained out to six years of follow-up. Within the class, mirtazapine carried the highest signal. Among SSRIs specifically, the pattern is heterogeneous, with some agents weight-neutral in the short term and weight-gaining longer term.
There’s a particular wrinkle worth knowing. Fluoxetine often produces modest weight loss in the first months, a finding that gave the early SSRIs a reputation as the “skinny antidepressants,” but that effect tends to fade by month four or six, and is sometimes reversed at twelve months. Patients who feel their body changing six to twelve months into treatment are not imagining it.
So the first honest sentence is this: there is no antidepressant that is reliably weight-neutral for everyone over years of use, and patients deserve to know that going in.
What depression itself does
The other half of the picture is that depression isn’t weight-neutral either. A meta-analysis of nineteen prospective studies found a bidirectional relationship: depressed people had a 37% higher risk of developing obesity, and people with obesity had an 18% higher risk of developing depression. Some of this is shared biology, with chronic inflammation, HPA axis dysregulation, and disrupted sleep all implicated. Some of it is behavioural, since depression flattens motivation, blunts the reward people normally get from movement, and shifts food choices. And some of it is iatrogenic, with the medications used to treat the depression contributing too.
This matters because the counterfactual to a person gaining 8 kg on an antidepressant is not always the same person at their original weight. Sometimes it is the same person, ten kilos heavier still, plus untreated depression. The arithmetic of trade-offs has to start with the right baseline.
The newer wrinkle: emotional blunting and motivation
Recent literature has put a name to something patients have described for years. Antidepressant-induced emotional blunting, a flattening of both negative and positive emotional response, is reported in roughly 40 to 60% of people on SSRIs and SNRIs. The proposed mechanism involves serotonin’s suppression of dopaminergic reward pathways, the same pathway that drives motivation, reward-seeking, and the pleasure people get from exertion and effort.
The clinical implication is uncomfortable. The medication that makes the bottom of depression survivable may, in some patients, also be dampening the thing they would need to use to manage their weight: the motivation to move, the satisfaction of effort, the reward signals that turn a walk into a habit. We don’t know how much of the weight gain on antidepressants is the drug acting directly on metabolism, how much is appetite, and how much is this quieter loss of the internal engine that drives activity. Most likely all three, in proportions that vary by person.
What GLP-1 medications do (and don’t do) in this picture
Patients on antidepressants who later access GLP-1 weight management therapy raise a fair question: does one undo the other?
The honest answer is the evidence so far is reassuring on weight, mixed on mood, and far from settled.
On weight: a post-hoc analysis of the STEP trials, presented at ObesityWeek in 2023, looked at participants who were on antidepressants at trial entry. Across all four STEP studies, those on antidepressants achieved clinically meaningful weight loss on semaglutide versus placebo, comparable to, and in some subgroups numerically greater than, participants not on antidepressants. Antidepressant use at baseline did not blunt the medication’s effect.
On mood: this is where the literature genuinely splits. A 2026 Swedish national cohort study published in Lancet Psychiatry, following nearly 100,000 people with pre-existing depression or anxiety who were also being treated with antidiabetic medication, found that semaglutide was associated with a 44% lower risk of worsening depression and a 38% lower risk of worsening anxiety during periods of use compared to non-use; liraglutide showed a smaller effect on depression only. Other large datasets, including a 2024 post-marketing cohort, have reported the opposite signal, with elevated rates of psychiatric adverse events. Both can be partly true: the population is heterogeneous, the confounders are immense, and regulators including the TGA, FDA and EMA continue to investigate the suicidality signal specifically.
What the evidence does not yet support is the conclusion that GLP-1 medications treat depression, or that they should be added to an antidepressant for mood reasons. They aren’t, and they shouldn’t. The case for them in this population is the same as it is in any other: clinical eligibility for weight management, properly assessed and supervised.
The questions medicine hasn’t finished answering
This is where we want to leave readers with the open questions rather than tidy answers, because the honest position is that medicine is still working them out.
When a patient on a weight-gaining antidepressant has gained 12 kg, is the right move to add a second medication to counteract the first, or to revisit the original prescription? At what point does the cumulative side-effect burden of stacked medications outweigh the benefit of each individual one? Who is responsible for that conversation: the GP, the psychiatrist, the obesity physician, the patient? Most patients don’t have all three of those people in the same room, ever.
How should a GP weigh emotional blunting against depression control, in a patient who says I’m not sad anymore, but I’m not anything? Is the muted motivation a side effect to manage around, or a signal that the medication is wrong? The literature offers strategies, including dose review, agent switching, and augmentation, but those are decisions for a treating prescriber, not a checklist.
And the deeper question: when we treat depression with a medication that promotes weight gain, then treat the weight gain with another medication, what are we actually doing? Are we layering treatments on a problem that was always one problem, with metabolic and mental health as a single system, or are we managing two diseases that genuinely require two different drugs? The science suggests it’s some of both, in proportions we can’t yet specify per patient.
What we think matters
We don’t have a position on whether someone should stay on their antidepressant, switch, taper, or add anything to it. Those are decisions for the person and their treating clinicians, made with their full history in front of them. What we do think is this:
Patients deserve the full picture before they consent to any of it. They deserve to know that weight is part of the antidepressant conversation, not a personal failing layered on top of one. They deserve a clinical team that talks across the mental health and metabolic lines rather than handing them off between specialties. And they deserve the honesty that says: we are still learning what the right answer is.
If you’re sitting in this bind right now, feeling better, feeling heavier, and feeling unsure whether the medication is helping or hurting, that is a conversation worth having with your GP. Not a conversation to delay, and not a conversation to have with the internet alone.
References used in this piece are listed in the sources log. This article does not constitute medical advice. Decisions about antidepressant therapy, weight management medication, or any combination should be made with your treating clinicians.